Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: An approach to reducing dyskinesia without exacerbating parkinsonism?

Journal of Pharmacology and Experimental Therapeutics

Volumn 339, Issue 1, 2011, Pages 2-8

  Huot, Philippe ^a,b   Fox, Susan H ^a,b   Newman Tancredi, Adrian ^c   Brotchie, Jonathan M ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b TORONTO WESTERN HOSPITAL   (Canada)

^c NeuroAct Communication   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; BUSPIRONE; CLOZAPINE; DOPAMINE; GLUTAMIC ACID; LEVODOPA; PIMAVANSERIN; QUETIAPINE; RITANSERIN; SARIZOTAN; SEROTONIN 1 AGONIST; SEROTONIN 1 RECEPTOR; SEROTONIN 2 ANTAGONIST; SEROTONIN 2 RECEPTOR; TANDOSPIRONE;

BRAIN REGION; CORPUS STRIATUM; DISEASE EXACERBATION; DRUG SELECTIVITY; DRUG TARGETING; DYSKINESIA; HUMAN; NEUROTRANSMITTER RELEASE; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; RAPHE NUCLEUS; REVIEW; SUBSTANTIA NIGRA;

ANIMALS; ANTIPARKINSON AGENTS; DYSKINESIA, DRUG-INDUCED; HUMANS; MPTP POISONING; PARKINSON DISEASE; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN AGENTS; SYNAPTIC TRANSMISSION;

EID: 80053169158     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.184093     Document Type: Review

References (76)

1. Aghajanian GK and Marek GJ (1999) Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release. Brain Res 825:161-171. (Pubitemid 29222872)
2. Barnes NM and Sharp T (1999) A review of central 5-HT receptors and their function. Neuropharmacology 38:1083-1152. (Pubitemid 29292403)
3. Baron MS and Dalton WB (2003) Quetiapine as treatment for dopaminergic-induced dyskinesias in Parkinson's disease. Mov Disord 18:1208-1209. (Pubitemid 37336953)
4. Bartoszyk GD, Van Amsterdam C, Greiner HE, Rautenberg W, Russ H, and Seyfried CA (2004) Sarizotan, a serotonin 5-HT1A receptor agonist and dopamine receptor ligand. 1. Neurochemical profile. J Neural Transm 111:113-126. (Pubitemid 38283223)
5. Berg KA and Clarke WP (2006) Development of functionally selective agonists as novel therapeutic agents. Drug Discov Today Ther Strat 3:421-428. (Pubitemid 46098475)
6. Bonifati V, Fabrizio E, Cipriani R, Vanacore N, and Meco G (1994) Buspirone in levodopa-induced dyskinesias. Clin Neuropharmacol 17:73-82. (Pubitemid 24046709)
7. Bruins Slot LA, De Vries L, Newman-Tancredi A, and Cussac D (2006) Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase. Eur J Pharmacol 534:63-70. (Pubitemid 43384184)
8. 2A receptors in afferents of the rat striatum. Synapse 39:297-304.
9. Buritova J, Berrichon G, Cathala C, Colpaert F, and Cussac D (2009) Region-specific changes in 5-HT1A agonist-induced extracellular signal-regulated kinases 1/2 phosphorylation in rat brain: a quantitative ELISA study. Neuropharmacology 56:350-361.
10. 1A receptor agonist 8-OHDPAT prevents prefrontocortical glutamate and serotonin release in response to blockade of cortical NMDA receptors. J Neurochem 96:853-860.
11. Carta M, Carlsson T, Kirik D, and Björklund A (2007) Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 130:1819-1833. (Pubitemid 47343795)
12. Carta M, Carlsson T, Muñoz A, Kirik D, and Björklund A (2008) Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias. Prog Brain Res 172:465-478.
13. Chen J, Shen C, and Meller E (2002) 5-HT1A receptor-mediated regulation of mitogen-activated protein kinase phosphorylation in rat brain. Eur J Pharmacol 452:155-162. (Pubitemid 35283926)
14. Clarke WP, Yocca FD, and Maayani S (1996) Lack of 5- hydroxytryptamine1Amediated inhibition of adenylyl cyclase in dorsal raphe of male and female rats. J Pharmacol Exp Ther 277:1259-1266.
15. Cornfield LJ, Lambert G, Arvidsson LE, Mellin C, Vallgårda J, Hacksell U, and Nelson DL (1991) Intrinsic activity of enantiomers of 8-hydroxy-2-(di-npropylamino) tetralin and its analogs at 5-hydroxytryptamine1A receptors that are negatively coupled to adenylate cyclase. Mol Pharmacol 39:780-787.
16. Cowen DS, Johnson-Farley NN, and Travkina T (2005) 5-HT receptors couple to activation of Akt, but not extracellular-regulated kinase (ERK), in cultured hippocampal neurons. J Neurochem 93:910-917. (Pubitemid 40695750)
17. Cruz DA, Eggan SM, Azmitia EC, and Lewis DA (2004) Serotonin1A receptors at the axon initial segment of prefrontal pyramidal neurons in schizophrenia. Am J Psychiatry 161:739-742. (Pubitemid 38445520)
18. Cussac D, Boutet-Robinet E, Ailhaud MC, Newman-Tancredi A, Martel JC, Danty N, and Rauly-Lestienne I (2008) Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells. Eur J Pharmacol 594:32-38.
19. Dekundy A, Lundblad M, Danysz W, and Cenci MA (2007) Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav Brain Res 179:76-89. (Pubitemid 46441485)
20. DeLong MR and Wichmann T (2007) Circuits and circuit disorders of the basal ganglia. Arch Neurol 64:20-24. (Pubitemid 46072419)
21. Dupre KB, Ostock CY, Eskow Jaunarajs KL, Button T, Savage LM, Wolf W, and Bishop C (2011) Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats. Exp Neurol 229:288-299.
22. Dupuis DS, Tardif S, Wurch T, Colpaert FC, and Pauwels PJ (1999) Modulation of 5-HT1A receptor signalling by point-mutation of cysteine351 in the rat Galpha;o protein. Neuropharmacology 38:1035-1041. (Pubitemid 29240620)
23. Durif F, Debilly B, Galitzky M, Morand D, Viallet F, Borg M, Thobois S, Broussolle E, and Rascol O (2004) Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology 62:381-388. (Pubitemid 38200847)
24. Fahn S (2008) The history of dopamine and levodopa in the treatment of Parkinson's disease. Mov Disord 23(Suppl 3):S497-S508.
25. Ferguson M, Nayyar T, and Ansah TA (2010) 5-HT2A receptor antagonist M100907 decreases striatal extracellular glutamate in MPTP mouse model of Parkinson's disease, at the Society for Neuroscience Annual Meeting; 2010 Nov. 13-17; San Diego, CA. Society for Neuroscience, Washington, DC.
26. Fox S and Brotchie J (1996) Normethylclozapine potentiates the action of quinpirole in the 6-hydroxydopamine lesioned rat. Eur J Pharmacol 301:27-30.
27. Goetz CG, Damier P, Hicking C, Laska E, Müller T, Olanow CW, Rascol O, and Russ H (2007) Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov Disord 22:179-186. (Pubitemid 46374758)
28. Goetz CG, Laska E, Hicking C, Damier P, Müller T, Nutt J, Warren Olanow C, Rascol O, and Russ H (2008) Placebo influences on dyskinesia in Parkinson's disease. Mov Disord 23:700-707.
29. Grégoire L, Samadi P, Graham J, Bédard PJ, Bartoszyk GD, and Di Paolo T (2009) Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys. Parkinsonism Relat Disord 15:445-452.
30. Hamik A, Oksenberg D, Fischette C, and Peroutka SJ (1990) Analysis of tandospirone (SM-3997) interactions with neurotransmitter receptor binding sites. Biol Psychiatry 28:99-109. (Pubitemid 20226391)
31. Hely MA, Morris JG, Reid WG, and Trafficante R (2005) Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 20:190-199. (Pubitemid 40361122)
32. 1A receptors in the MPTP-lesioned macaque. Neurobiol Aging doi:10.1016/j.neurobiolaging.2010.09.011.
33. 2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPA. Neurobiol Aging doi:10.1016/j.neurobiolaging.2010.1004. 1035.
34. Iravani MM, Tayarani-Binazir K, Chu WB, Jackson MJ, and Jenner P (2006) In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with increased motor disability. J Pharmacol Exp Ther 319: 1225-1234.
35. 3H]8-OH-DPAT labels a 5-HT site coupled to inhibition of phosphoinositide hydrolysis in the dorsal raphe. Eur J Pharmacol 329:99-106.
36. Kannari K, Kurahashi K, Tomiyama M, Maeda T, Arai A, Baba M, Suda T, and Matsunaga M (2002) [Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson's disease]. No To Shinkei 54:133-137.
37. Kenakin T (2011) Functional selectivity and biased receptor signaling. J Pharmacol Exp Ther 336:296-302.
38. Lejeune F, Newman-Tancredi A, Audinot V, and Millan MJ (1997) Interactions of (+)- and (-)-8- and 7-hydroxy-2-(di-n-propylamino)tetralin at human (h)D3, hD2, and h serotonin1A receptors and their modulation of the activity of serotoninergic and dopaminergic neurones in rats. J Pharmacol Exp Ther 280:1241-1249. (Pubitemid 27166720)
39. Leysen JE, Gommeren W, Van Gompel P, Wynants J, Janssen PF, and Laduron PM (1985) Receptor-binding properties in vitro and in vivo of ritanserin: a very potent and long acting serotonin-S2 antagonist. Mol Pharmacol 27:600-611. (Pubitemid 15010691)
40. 1A receptor agonist, at postsynaptic 5-HT1A receptors. Br J Pharmacol 160:1929-1940.
41. Lucas G and Spampinato U (2000) Role of striatal serotonin2A and serotonin2C receptor subtypes in the control of in vivo dopamine outflow in the rat striatum. J Neurochem 74:693-701. (Pubitemid 30053742)
42. Ludwig CL, Weinberger DR, Bruno G, Gillespie M, Bakker K, LeWitt PA, and Chase TN (1986) Buspirone, Parkinson's disease, and the locus ceruleus. Clin Neuropharmacol 9:373-378. (Pubitemid 16009219)
43. Maertens de Noordhout A and Delwaide PJ (1986) Open pilot trial of ritanserin in parkinsonism. Clin Neuropharmacol 9:480-484. (Pubitemid 17196765)
44. Mannoury la Cour C, El Mestikawy S, Hanoun N, Hamon M, and Lanfumey L (2006)Regional differences in the coupling of 5-hydroxytryptamine-1A receptors to G proteins in the rat brain. Mol Pharmacol 70:1013-1021. (Pubitemid 44268458)
45. Marin C, Aguilar E, Rodríguez-Oroz MC, Bartoszyk GD, and Obeso JA (2009) Local administration of sarizotan into the subthalamic nucleus attenuates levodopainduced dyskinesias in 6-OHDA-lesioned rats. Psychopharmacology (Berl) 204: 241-250.
46. 1C]WAY 100635 and positron emission tomography in humans. Neuropsychopharmacology 24:209-229.
47. Meco G, Marini S, Linfante I, Modarelli F, and Agnoli A (1988) Controlled singleblind crossover study of ritanserin and placebo in L-dopa-induced dyskinesias in Parkinson's disease. Curr Ther Res 43:262-270. (Pubitemid 18079419)
48. Mengod G, Vilaró MT, Raurich A, López-Giménez JF, Cortés R, and Palacios JM (1996) 5-HT receptors in mammalian brain: receptor autoradiography and in situ hybridization studies of new ligands and newly identified receptors. Histochem J 28:747-758. (Pubitemid 26414165)
49. Mills R, Revell S, Bahr D, Williams H, Johnson A and Friedman JH (2008) A double-blind, placebo-controlled, dose-escalation trial of pimavanserin in Parkinson's disease and psychosis. Mov Disord 23:S221-S222.
50. 2+ mobilizing agents mimic serotonin 5-HT2A facilitation of N-methyl-D-aspartate depolarization. Behav Brain Res 73:273-275.
51. 1A receptors: preferential postsynaptic activity for improved therapy of CNS disorders. Neuropsychiatry 1:149-164.
52. Newman-Tancredi A, Assié MB, Leduc N, Ormière AM, Danty N, and Cosi C (2005) Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia. Int J Neuropsychopharmacol 8:341-356. (Pubitemid 41002489)
53. 35S] GTPγS binding study. Eur J Pharmacol 355: 245-256.
54. 1A receptor properties. Psychopharmacology (Berl) 216:451-473.
55. Newman-Tancredi A, Martel JC, Assié MB, Buritova J, Lauressergues E, Cosi C, Heusler P, Bruins Slot L, Colpaert FC, Vacher B, et al. (2009) Signal transduction and functional selectivity of F15599, a preferential post-synaptic 5-HT1A receptor agonist. Br J Pharmacol 156:338-353.
56. Nordström AL, Farde L, Nyberg S, Karlsson P, Halldin C, and Sedvall G (1995) D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 152:1444-1449.
57. Olanow CW, Damier P, Goetz CG, Mueller T, Nutt J, Rascol O, Serbanescu A, Deckers F, and Russ H (2004) Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin Neuropharmacol 27:58-62. (Pubitemid 38569176)
58. Ostock CY, Dupre KB, Eskow Jaunarajs KL, Walters H, George J, Krolewski D, Walker PD, and Bishop C (2011) Role of the primary motor cortex in L-DOPA-induced dyskinesia and its modulation by 5-HT1A receptor stimulation. Neuropharmacology 61:753-760.
59. Palchaudhuri M and Flügge G (2005) 5-HT1A receptor expression in pyramidal neurons of cortical and limbic brain regions. Cell Tissue Res 321:159-172. (Pubitemid 41127024)
60. Pehek EA, Nocjar C, Roth BL, Byrd TA, and Mabrouk OS (2006) Evidence for the preferential involvement of 5-HT2A serotonin receptors in stress- and druginduced dopamine release in the rat medial prefrontal cortex. Neuropsychopharmacology 31:265-277. (Pubitemid 43113392)
61. Pompeiano M, Palacios JM, and Mengod G (1994) Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HT2C receptors. Brain Res Mol Brain Res 23:163-178.
62. 11C]raclopride. J Psychopharmacol 16:195-199.
63. Reddy S, Factor SA, Molho ES, and Feustel PJ (2002) The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia. Mov Disord 17:676-681. (Pubitemid 41295006)
64. Roberts C (2006) ACP-103, a 5-HT2A receptor inverse agonist. Curr Opin Investig Drugs 7:653-660.
65. Santana N, Bortolozzi A, Serrats J, Mengod G, and Artigas F (2004) Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex. Cereb Cortex 14:1100-1109. (Pubitemid 39258165)
66. Schmid CL and Bohn LM (2010) Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a β-arrestin2/Src/Akt signaling complex in vivo. J Neurosci 30:13513-13524.
67. Schmid CL, Raehal KM, and Bohn LM (2008) Agonist-directed signaling of the serotonin 2A receptor depends on β-arrestin-2 interactions in vivo. Proc Natl Acad Sci U S A 105:1079-1084. (Pubitemid 351282084)
68. Smith LA, Jackson MJ, Hansard MJ, Maratos E, and Jenner P (2003) Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naive MPTPtreated common marmosets: effect of dose, frequency of administration, and brain exposure. Mov Disord 18:487-495. (Pubitemid 36656532)
69. Sprouse JS and Aghajanian GK (1988) Responses of hippocampal pyramidal cells to putative serotonin 5-HT1A and 5-HT1B agonists: a comparative study with dorsal raphe neurons. Neuropharmacology 27:707-715.
70. Tamaoki S, Yamauchi Y, Nakano Y, Sakano S, Asagarasu A, and Sato M (2007) Pharmacological properties of 3-amino-5,6,7,8-tetrahydro-2-[4-[4-(quinolin-2- yl)piperazin-1-yl]butyl]qui nazolin-4(3H)-one (TZB-30878), a novel therapeutic agent for diarrhea-predominant irritable bowel syndrome (IBS) and its effects on an experimental IBS model. J Pharmacol Exp Ther 322:1315-1323. (Pubitemid 47295803)
71. Vanover KE, Betz AJ, Weber SM, Bibbiani F, Kielaite A, Weiner DM, Davis RE, Chase TN, and Salamone JD (2008) A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model. Pharmacol Biochem Behav 90:540-544.
72. Vanover KE, Weiner DM, Makhay M, Veinbergs I, Gardell LR, Lameh J, Del Tredici AL, Piu F, Schiffer HH, Ott TR, et al. (2006) Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)- N©-(4-(2-methylpropyloxy) phenylmethyl)carbamide(2R,3R)- dihydroxybutanedioate (2:1) (ACP- 103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist. J Pharmacol Exp Ther 317:910-918.
73. Visanji NP, Gomez-Ramirez J, Johnston TH, Pires D, Voon V, Brotchie JM, and Fox SH (2006) Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov Disord 21:1879-1891. (Pubitemid 44848934)
74. Wiesel FA, Nordström AL, Farde L, and Eriksson B (1994) An open clinical and biochemical study of ritanserin in acute patients with schizophrenia. Psychopharmacology (Berl) 114:31-38. (Pubitemid 24150517)
75. Willins DL, Deutch AY, and Roth BL (1997) Serotonin 5-HT2A receptors are expressed on pyramidal cells and interneurons in the rat cortex. Synapse 27:79-82. (Pubitemid 27327604)
76. Wolters EC, Hurwitz TA, Mak E, Teal P, Peppard FR, Remick R, Calne S, and Calne DB (1990) Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology 40:832-834. (Pubitemid 20159625)